Carrier proteins-based boron delivery to tumor

Appl Radiat Isot. 2020 Mar:157:109011. doi: 10.1016/j.apradiso.2019.109011. Epub 2019 Nov 30.

Abstract

The conjugation of maleimide-functionalized closo-dodecaborate (MID) to transferrin (TF), which has no free SH cysteine residue, proceeded at room temperature for 12 h in PBS buffer (pH = 7.4). MID-TF conjugates were accumulated into the cells in the time- and concentration-dependent manners through the TF receptor mediated mechanism. In vivo biodistribution study of MID-TF conjugates in colon 26-bearing mice revealed the time-dependent selective accumulation of MID-TF conjugates into tumor very similar to that of MID-BSA. The tumor boron concentration of MID-BSA was higher than that of MID-TF conjugates (62 ppm vs. 20 ppm at a dose of 30 mg [B]/kg) 12 h after administration, suggesting that the EPR effect is not remarkably observed in the case of MID-TF conjugates because TF has smaller molecular weight than BSA (48 kDa vs. 68 kDa).

MeSH terms

  • Animals
  • Boron / administration & dosage*
  • Boron Neutron Capture Therapy / methods*
  • Carrier Proteins / metabolism*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / therapy*
  • Drug Delivery Systems*
  • HeLa Cells
  • Heterografts
  • Humans
  • Maleimides / chemistry
  • Mice
  • Receptors, Transferrin / metabolism
  • Tissue Distribution
  • Transferrin / chemistry

Substances

  • Carrier Proteins
  • Maleimides
  • Receptors, Transferrin
  • Transferrin
  • maleimide
  • Boron